|
Items
|
Participants
|
|---|
|
No. of patients (male/female)
|
10 (5/5)
|
|
Age (years)
|
64.1 ± 10.6
|
|
Duration of RA (years)
|
8.4 ± 11.0
|
|
Cr (mg/dL)
|
0.66 ± 0.12
|
|
BUN (mg/dL)
|
15.6 ± 4.9
|
|
AST (IU/L)
|
20.5 ± 3.3
|
|
ALT (IU/L)
|
23.3 ± 11.6
|
|
MCV (fL)
|
97.8 ± 2.5
|
|
CRP (mg/dL)
|
0.2 ± 0.2
|
|
SDAI
|
5.4 ± 4.0
|
|
DAS28-CRP
|
2.1 ± 0.8
|
|
MMP-3 (ng/mL)
|
130.2 ± 88.6
|
|
MTX (mg/week)
|
7.0 ± 3.0
|
|
MTX dosage at first dose each week
|
|
4 mg (No. of patients)
|
5
|
|
2 mg (No. of patients)
|
5
|
|
SASP (mg/day)
|
1000 ± 0
|
|
PSL (mg/day)
|
2.7 ± 2.7
|
|
No. of drugs being taken
|
6.0 ± 2.1
|
-
Cr Serum creatinine, BUN blood urea nitrogen, AST aspartate aminotransferase, ALT alanine aminotransferase, MCV mean corpuscular hemoglobin, CRP C-reactive protein, SDAI simplified disease activity index, DAS28-CRP disease activity score-C reactive protein, MMP-3 matrix metalloproteinase-3, MTX methotrexate, SASP salazosulfapyridine and PSL prednisolone. Data are mean ± SD
